Recent

% | $
Quotes you view appear here for quick access.

Generex Biotechnology Corp. Message Board

  • blackjackkid41 blackjackkid41 Jan 8, 2013 1:55 PM Flag

    Pay No Attention to the Bashers

    Seriously, who in their Right Mind Shorts a .02 cent stock....Only a #$%$ The Potential Upside is open ended. Sure, GNBT may very well go under. That`s the risk you take. However, a positive announcement could cause the stock price to soar. So forget shorting a .02 stock! You could get your head handed to you.

    Consequently, in my opinion, 99% of the GNBT Bashers are literally LONG.

    Just think about it for a moment.

    However, there are a few on this board that got burned bad and have resorted to Bashing the company.
    One in particular is Tarpongrt, who has been very negative and critical of GNBT for the last two years+. RRtaxes is another one...but he gets off just seeing his posts and then runs to mommy and asks for another M&M. lol

    I bought 5000 shares of GNBT on 12/31/12 @ .0255/sh for a a big investment of $136.44. What the heck, GNBT owes me nothing. What do I have to lose!

    Best of luck to genuine Longs!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "Just think about it for a moment."

      I try:why a "genuine Long" posts this kind of pathetic,childish post,whit no real information?Desperation?Being scared?Blaming "bashers",messageboard on a bad investment is not very smart,anyway

    • Novel adjuvant therapy shows promise for women with a history of breast cancer in Phase II clinical trial

      A breast cancer vaccine already shown to elicit a powerful immune response in women with varying levels of HER2 expression has the ability to improve recurrence rates and is well tolerated in an adjuvant setting, according to new research from a clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

      The findings, released today, will be presented on Monday, June 4 in an oral presentation at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO). It builds on previous research showing the vaccine, known as AE37, to safely and effectively raise immunity against human epidermal growth factor receptor 2 (HER2) – an oncoprotein that promotes tumor growth and is expressed to some extent in 75-80% of breast cancer tumors.

      The researchers found that patients who received the vaccination had an estimated recurrence rate of 10.3% compared to 18% in the control group at a median follow up of 22 months. This represented a 43% reduction in the risk of recurrence.

      “The vaccine educates the immune system to recognize HER2 as an invader,” said Elizabeth Mittendorf, M.D., assistant professor in the Department of Surgical Oncology at MD Anderson and the trial’s national principal investigator. “By introducing it into women who have had breast cancer, our goal is to instruct the immune system to immediately recognize any recurring cancer cells and orchestrate an attack.”
      Novel adjuvant therapy shows promise for women with a history of breast cancer in Phase II clinical trial

      A breast cancer vaccine already shown to elicit a powerful immune response in women with varying levels of HER2 expression has the ability to improve recurrence rates and is well tolerated in an adjuvant setting, according to new research from a clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

      The findings, released today, will be presented on Monday, June 4 in an oral presentation at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO). It builds on previous research showing the vaccine, known as AE37, to safely and effectively raise immunity against human epidermal growth factor receptor 2 (HER2) – an oncoprotein that promotes tumor growth and is expressed to some extent in 75-80% of breast cancer tumors.

      The researchers found that patients who received the vaccination had an estimated recurrence rate of 10.3% compared to 18% in the control group at a median follow up of 22 months. This represented a 43% reduction in the risk of recurrence.

      “The vaccine educates the immune system to recognize HER2 as an invader,” said Elizabeth Mittendorf, M.D., assistant professor in the Department of Surgical Oncology at MD Anderson and the trial’s national principal investigator. “By introducing it into women who have had breast cancer, our goal is to instruct the immune system to immediately recognize any recurring cancer cells and orchestrate an attack.”

      Sentiment: Strong Buy

 
GNBT
0.0076+0.0003(+4.11%)Jun 24 3:58 PMEDT